1 Division of Gastroenterology, Department of Internal
Medicine, University of Marmara Medical School, Istanbul 81326;
2 Department of Computer Engineering, Boaziçi
University, Istanbul 80815; Departments of 3 Nuclear Medicine,
4 Biochemistry, 5 Biostatistics, and 6
Physiology, University of Marmara Medical School, Istanbul 81326, Turkey; and 7 Department of Clinical Biochemistry,
Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen; and
8 Department of Medical Physiology, The Panum Institute,
University of Copenhagen, DK-2200 Copenhagen, Denmark
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We investigated the
effect of acarbose, an -glucosidase and pancreatic
-amylase
inhibitor, on gastric emptying of solid meals of varying nutrient
composition and plasma responses of gut hormones. Gastric emptying was
determined with scintigraphy in healthy subjects, and all studies were
performed with and without 100 mg of acarbose, in random order, at
least 1 wk apart. Acarbose did not alter the emptying of a
carbohydrate-free meal, but it delayed emptying of a mixed meal and a
carbohydrate-free meal given 2 h after sucrose ingestion. In meal
groups with carbohydrates, acarbose attenuated responses of plasma
insulin and glucose-dependent insulinotropic polypeptide (GIP) while
augmenting responses of CCK, glucagon-like peptide-1 (GLP-1), and
peptide YY (PYY). With mixed meal + acarbose, area under the curve
(AUC) of gastric emptying was positively correlated with integrated
plasma response of GLP-1 (r = 0.68, P < 0.02). With the carbohydrate-free meal after sucrose and acarbose
ingestion, AUC of gastric emptying was negatively correlated with
integrated plasma response of GIP, implying that prior alteration of
carbohydrate absorption modifies gastric emptying of a meal. The
results demonstrate that acarbose delays gastric emptying of solid
meals and augments release of CCK, GLP-1, and PYY mainly by
retarding/inhibiting carbohydrate absorption. Augmented GLP-1 release
by acarbose appears to play a major role in the inhibition of gastric
emptying of a mixed meal, whereas CCK and PYY may have contributory roles.
insulin; diabetes; ileal brake; peptide YY; glucose-dependent insulinotropic polypeptide; blood glucose
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ACARBOSE, a complex
pseudooligosaccharide of microbial origin with an ability to bind
to -glucosidases and reversibly inhibit the activity of these
enzymes, possesses 15,000-fold higher affinity to sucrase than its
substrate sucrose, and its inhibitory potency on glycoamylase is higher
than that of sucrase (6). At the same time, this
pseudooligosaccharide inhibits pancreatic
-amylase activity in a
mixed noncompetitive manner by binding to amylase-substrate complexes
or to amylase molecules, resulting in abortive complexes (8). In healthy subjects oral ingestion of acarbose
dose-dependently decreases absorption of carbohydrates, increases their
ileal delivery, prolongs absorption time, and increases intestinal flow
rates (37, 46). Because of its postprandial blood glucose
suppressant effect, acarbose is currently used in the treatment of type
I and II diabetes mellitus (5, 21). In both healthy and
diabetic subjects, acarbose attenuates postprandial insulin and
glucose-dependent insulinotropic polypeptide (GIP) concentrations
(21, 36, 38, 49) while augmenting plasma glucagon-like
peptide-1 (GLP-1) (36), enteroglucagon (gut glucagon-like
immunoreactivity by earlier assays) (37, 38, 46) and
peptide YY (PYY) (10) levels compared with controls.
On nutrient absorption, GLP-1 is released from the L-type endocrine
cells of the intestine and stimulates insulin secretion from pancreatic
-cells, similar to the actions of GIP (16, 31). Hence,
GLP-1 and GIP are considered to be incretin hormones (16).
In addition, GLP-1 has gastrointestinal effects, some of which carry
potential physiological importance, such as inhibition of gastric
motility and acid secretion and induction of satiety (16,
33). PYY is also suggested to play a physiological role in the
inhibition of secretory and motor functions of the upper gut (1,
7, 34). Furthermore, GLP-1 and PYY are considered to be among
the hormonal mediators of the "ileocolonic brake" phenomenon
(7, 16, 34).
In healthy subjects, the effect of acarbose on gastric emptying of solid meals of varying nutrient composition is unknown. Among the determinants of gastric emptying rate are the intestinal nutrient-sensing mechanisms that detect nutrient composition and, accordingly, control food entry to the intestine via an array of complex neurohormonal pathways (12). The emptying rate of carbohydrates is tightly coupled to the energy density and volume of the meal (18, 47). Intraintestinal perfusion of carbohydrates suppresses antral contractions (14, 47), enhances pyloric tone (14), and inhibits gastric emptying via vagal and spinal capsaicin-sensitive afferent pathways (39). Theoretically, acarbose, by attenuating carbohydrate absorption, would suppress the neurohormonal nutrient-sensing mechanisms and hence accelerate gastric emptying. Alternatively, acarbose, by prolonging the absorption time of carbohydrates and increasing their delivery to the distal gut, would augment the neurohormonal sensing mechanisms and thus induce the ileocolonic brake phenomenon, which in turn would delay gastric emptying. Previous studies in healthy subjects documented that acarbose inhibits gastric emptying of a sucrose solution (38) and accelerates mouth-to-cecum transit time (24). On the other hand, in patients with type I diabetes, acarbose was shown to be without effect on the emptying of a mixed meal (21).
The previously documented features of acarbose-induced alteration of carbohydrate absorption and augmentation of GLP-1 and PYY release led us to postulate that in healthy subjects acarbose would delay gastric emptying of a solid mixed meal. A carbohydrate-free meal was included in our study design to determine whether the effect of acarbose on gastric emptying is specifically mediated by alteration of carbohydrate absorption. Postulating that acarbose enhances the intestinal inhibitory neurohormonal signals on gastric emptying and thus mimics the ileal brake effect, we also examined the emptying of a carbohydrate-free meal subsequent to a sucrose premeal. This last condition is also analogous to therapeutic administration of acarbose with meals because the drug is present in the small intestine at least 4 h after its oral ingestion (46). To document whether a relation exists between the rate of gastric emptying and the plasma hormones, which were previously shown to be augmented by acarbose, we measured plasma responses to GLP-1 and PYY. Plasma responses to CCK were also studied because of this peptide's well-established inhibitory role in gastric emptying, including emptying of carbohydrates (9, 30, 39). Carbohydrate absorption was monitored by measuring blood glucose, plasma GIP, and serum insulin concentrations.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subjects. Thirty-seven healthy male subjects (mean age 23.2 ± 1.5 yr, range 20-26; mean body mass index = 22.9 ± 2.7 kg/m2), who were recruited by advertisement, participated in the study. None of the subjects had chronic diseases or had had abdominal surgery, except appendectomy. Subjects were not on any chronic treatment and did not take any medications within the week before the experiment. Written informed consent was obtained from each subject, and the institutional ethics committee approved the study protocol. Two subjects participated in two groups of studies and one subject participated in three groups of studies.
Study design. All studies were performed in the morning hours after a 12-h fast. Smoking and chewing gum were not allowed 12 h before or during the study. An antecubital vein was cannulated with an indwelling catheter to be used for sampling of blood glucose and hormone responses. Scintigraphic gastric emptying of solid meals was determined using 99mTc-tin colloid-labeled egg as the radioactive component of the meal.
The effect of acarbose on gastric emptying of a mixed-nutrient meal (n = 14), a carbohydrate-free meal (n = 9), or a carbohydrate-free meal after sucrose ingestion (n = 12) was determined (Table 1). In all study groups, each subject randomly underwent two sets of experiments, with or without acarbose administration, at least 1 wk apart. In studies with acarbose, subjects ingested a 100-mg tablet of acarbose (Glucobay; Bayer, Leverkusen, Germany) dissolved in light tea (200 ml, Ceylon Breakfast; Twinings, London, UK) with meals. In studies without acarbose, subjects ingested the same volume of tea (Table 1). In the group with sucrose ingestion, 50 g of sucrose dissolved in 500 ml of water with or without 100 mg of acarbose was ingested 120 min before a carbohydrate-free meal. All solid meals were ingested within 8 min and immediately after scintigraphic acquisitions were obtained. In addition, to determine the effect of acarbose on plasma hormone responses in the absence of nutrients, 500 ml of water were ingested with or without 100 mg of acarbose, and plasma samples were obtained for hormone assays (n = 6).
|
Measurement and analysis of gastric emptying. One millicurie of 99mTc-tin colloid was mixed with the egg component of the meal and cooked with butter until a firm consistency was achieved. Anatomic markers labeled with low-activity 99mTcO4 were attached to the skin at the sternal notch and both anterior superior iliac spines. One-minute anterior and, immediately afterward, posterior scintigraphic acquisitions were obtained in the sitting position using a large field-of-view gamma camera fitted with a low-energy collimator and interfaced with a dedicated computer system (GE XRT; General Electric Medical Systems, Milwaukee, WI). Technetium counts were obtained with a 20% energy window with peak set at 140 keV. The scintigraphic acquisitions were obtained immediately after ingestion of the test meal, every 5 min for the first 30 min and every 10 min thereafter until ~10% of the counts remained in the stomach. Subjects were allowed to ambulate during intervals between image acquisitions. A region of interest was manually outlined corresponding to the stomach for each scintigraphic image. Corrections were made for decay of the radioactivity. Geometric means of the counts obtained in the anterior and posterior projections were calculated for attenuation correction according to the following formula: geometric mean = square root of (anterior × posterior) counts. Data were normalized to 100% based on total gastric counts obtained immediately after ingestion of the radiolabeled meal.
In vivo and in vitro radionuclide labeling stability tests were performed in two subjects as previously described (29). In vitro studies revealed that 93.5% of the radioactivity was in the solid phase 2 h after incubation of the meal with gastric juice. The percentage of the administered 99mTc radioactivity in the blood was 0.75, 1.43, and 1.24 after 1, 2, and 3 h, respectively. Percent gastric retention radioactivity of each subject was analyzed using the modified power exponential function as described by Siegel et al. (48), according to which y(t) is the fractional meal retention at time t, k is the gastric emptying rate (in minBlood specimens.
Venous blood samples for GIP, CCK, GLP-1, and PYY immunoassays were
obtained from an indwelling venous catheter at 15 min and immediately
before test meals (0 min) and at appropriate intervals thereafter, as
depicted in Figs. 3-5. In the nonnutrient drink group, blood was
sampled at 5-min intervals for the first 15 min and then every 15 min
for 150 min. Venous blood was collected into chilled tubes containing
aprotinin (500 KIU/ml of blood; Trasylol, Leverkusen, Germany) and EDTA
(1 mg/ml of blood; Merck, Darmstadt, Germany) and was centrifuged at
4°C, and plasma was immediately stored at
20°C until assayed. In
subjects who ingested carbohydrate-containing meals, blood was
collected into blank tubes and centrifuged at 4°C, serum was stored
at
20°C for insulin determinations, and blood was collected into
NaF (Merck)-containing tubes for glucose determination.
Analytical procedures. Glucose was measured with the glucose oxidase method, using an enzymatic colorimetric assay (Glucose GOD-PAP, BM/Hitachi 917 analyzer; Boehringer Mannheim, Mannheim, Germany).
Insulin concentrations were measured using a solid phase, two-site chemiluminescent enzyme-labeled immunometric assay (Immulite Insulin; Diagnostic Products, Los Angeles, CA) in the mixed meal group. The detection limit of the assay was ~2 µIU/ml, and the intra-assay coefficient of variation (CV) was <5%. In the study group with the carbohydrate-free meal after sucrose ingestion, insulin was measured using a solid-phase 125I radioimmunoassay (Coat-A-Count Insulin; Diagnostic Products). The detection limit of the assay was 1.2 µIU/ml, and intra-assay CV was <10%. Plasma concentrations of CCK, GIP, GLP-1, and PYY were measured as previously described (17, 22, 35, 41). CCK was assayed using an antibody (92128) raised in rabbits against an O-sulfated human CCK-12 analog (41). Antibody 92128 binds all the bioactive forms of CCK with equimolar potency and displays no reactivity with gastrin (41). The tracer used was the Bolton-Hunter labeled sulfated CCK-8 (125I-CCK-8). Separation of antibody-bound and free tracer was achieved by using plasma-coated charcoal. The detection limit of the assay was 0.1 pmol/l. The intra- and interassay variation at different concentrations within the working range of the assay ranged between 5% and 15%. All samples were assayed in duplicate. Plasma GIP was measured using COOH-terminally directed antibody R65 (22). The sensitivity of the radioimmunoassay was <1 pmol/l. Intra-assay CV was <6% at 20 pmol/l of plasma GIP, and interassay CV was ~15-20%. Plasma concentrations of GLP-1 were assayed with antibody 89390 at a final dilution of 1:200,000 (35). Antibody 89390 crossreacts 100% with the amidated COOH terminus of GLP-1-(7-36)amide and its immediate metabolite GLP-1-(9-36)amide but crossreacts <0.1% with GLP-1-(7-37) and fragment 1-35. The experimental detection limit was 1 pmol/l, and the intra-assay CV was 6%. Plasma concentrations of PYY were measured with antiserum 8412-211 (a gift from R. Håkanson, Dept. of Pharmacology, University of Lund, Sweden) by methods previously described (17). The detection limit of the assay was <1 pmol/l, and intra-assay CV was <5%.Statistical analysis.
The data are presented as means ± SE or medians (ranges)
according to the distribution of data. Basal plasma hormone
concentrations were calculated by taking an average of 15 min and 0 min values. Integrated responses of area under curve (AUC) were
calculated according to the trapezoidal rule. To determine whether meal
ingestion altered basal plasma determinations, repeated-measures ANOVA
with time as a main factor was applied to plasma hormone and glucose concentrations followed by Newman-Keuls test. To determine the effect
of acarbose administration on hormonal responses, two-way ANOVA was
used, with time and treatment as main factors. Paired data at specific
time points were compared by using Wilcoxon signed-rank test or paired
t-test, as appropriate. Correlations between gastric emptying data and hormonal responses were investigated by using Pearson's test. Multivariate stepwise regression analysis was used to
determine the relationship between dependent and independent variables.
Differences were considered statistically significant if P
< 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Acarbose administered with sucrose caused flatulence in three subjects, and two of the three reported diarrhea at ~80 min after the sucrose meal. No symptoms were reported in other study groups.
Blood glucose and serum insulin.
The mixed meal alone did not increase blood glucose concentrations
except at 40 min (P < 0.001), whereas sucrose ingestion increased glucose levels between 0 and 60 min compared with the basal
value (P <0.05-0.001). Acarbose blunted blood glucose
concentrations in both groups (Fig. 1).
Nevertheless, integrated responses of glucose with acarbose were
similar to control values because of the control group's postpeak
glucose concentrations, which were below basal values (Fig. 1).
Acarbose attenuated responses of serum insulin in both groups (Fig. 1).
|
Gastric emptying. In all study groups, the modified power exponential function provided a good fit to each individual gastric emptying curve, and the R2 value was >0.95.
As shown in Table 2 and Fig. 2A, acarbose administration with the mixed meal did not alter the lag phase but prolonged T50 and decreased gastric emptying rate k by ~25%. The median AUC (min
|
|
|
Plasma hormone responses. Ingestion of water with or without acarbose did not alter plasma GIP, GLP-1, and PYY levels compared with the respective basal values. Ingestion of water with acarbose significantly increased plasma CCK concentrations compared with the basal value of 0.75 ± 0.13 pmol/l (1.2 ± 0.19 and 1.3 ± 0.17 pmol/l at 5 and 10 min, respectively; P <0.05), whereas water alone did not appreciably alter CCK levels.
Mixed meal group.
Plasma samples of only 12 of the 14 study subjects were available for
hormone assays for technical reasons. In response to the meal plasma
GIP and CCK concentrations were significantly elevated in groups with
and without acarbose (P < 0.1-0.001). However,
integrated GIP response of the acarbose group was significantly lower
and CCK response was significantly higher compared with control values
(Fig. 3, A and B,
insets).
|
Carbohydrate-free meal group.
Meal ingestion caused significant elevation of plasma GIP
and CCK in groups with and without acarbose (P < 0.001), and integrated responses covering the study period were similar
between acarbose and control groups (Fig.
4, A and B,
insets). However, plasma GIP showed significant differences
between groups with and without acarbose in the inclination and
declination portions of the time-response curve (Fig. 4A).
|
Carbohydrate-free meal after sucrose ingestion group.
As depicted in Fig. 5, acarbose
substantially altered all plasma hormone responses to the sucrose
premeal and modified GIP and PYY responses to the carbohydrate-free
meal. Plasma GIP was abolished and attenuated in response to sucrose
and carbohydrate-free meals, respectively (Fig. 5A).
|
Correlation of plasma hormone responses with gastric emptying.
The delayed gastric emptying time induced by acarbose in the mixed meal
group was positively correlated with the integrated GLP-1 response
(AUC, r = 0.68, P < 0.02; Fig.
6A). Multivariate stepwise
regression analysis demonstrated that integrated plasma GLP-1 response
was the only significant determinant of gastric emptying AUC
(r2 = 0.46, P < 0.03).
|
Correlation between hormonal responses. There was a weak correlation between integrated responses of GLP-1 and PYY (r = 0.58, P < 0.5) in the mixed meal acarbose group. A correlation was also observed between integrated responses of GLP-1 and PYY in the acarbose carbohydrate-free meal after sucrose ingestion group (0-240 min) (r = 0.68, P < 0.01). Integrated GLP-1 during the same period was also positively correlated with insulin response (r = 0.75, P < 0.01).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our results demonstrate that acarbose inhibits emptying of carbohydrate-containing meals, whereas it does not alter the emptying of meals composed of fat and protein. In the case of delayed emptying of a mixed meal by acarbose, the duration of the lag phase was similar to that of control, implying that acarbose and carbohydrates had to be emptied from the stomach to initiate the intestinal inhibitory signals that modulate gastric motor activity. On the other hand, acarbose caused prolongation of both the lag phase and gastric half-emptying time of a carbohydrate-free meal subsequent to sucrose ingestion, demonstrating that the intestinal inhibitory signals were already operative while the carbohydrate-free meal was being ingested. The unaltered gastric emptying of a solid mixed meal by acarbose demonstrated in type I diabetic subjects by Juntti-Berggren et al. (21) may be caused by the presence of autonomic neuropathy, which may have blunted the effect of acarbose on intestinal neurohormonal signaling to modify gastric motility. Alternatively, the different results obtained by us and the aforementioned study may be caused by the different experimental designs used.
Carbohydrate absorption is tightly coupled to GIP release (34). Confirming previous findings (36, 46, 49), we observed that acarbose administration causes considerable inhibition of carbohydrate absorption, as reflected by attenuated plasma insulin, GIP, and blood glucose concentrations. It is possible that in healthy and probably in diabetic subjects the postprandial blood glucose-lowering effect of acarbose is partially mediated by its ability to inhibit gastric emptying.
There may be several mechanisms responsible for inhibition of gastric
emptying that result from alteration of -glucosidase and
-amylase
activities by acarbose, and these mechanisms may be particular to the
timing of carbohydrate intake. It is conceivable that the inhibitory
action of acarbose on gastric emptying is mediated through enhancement
of the intestinal neurohormonal inhibitory signals by exposure of a
longer length of intestine to the carbohydrate absorptive process,
prolongation of carbohydrate absorption time, and increased delivery of
unabsorbed carbohydrate residues to the ileum and distally. This
assumption is supported by earlier findings demonstrated in humans that
gastric emptying of solid nutrients is delayed by slowly absorbed
carbohydrates as opposed to rapidly absorbed isocaloric carbohydrates
(27). Similarly, a longer length of canine intestine
exposed to glucose elicits a higher degree of inhibition of gastric
emptying compared with a shorter length of intestinal exposure
(26). In addition, unabsorbed carbohydrate residues may
have played roles in our findings by increasing osmolality and/or
through conversion to short-chain fatty acids (SCFAs), which inhibit
gastric motility when perfused into the distal bowel (45).
The absorption of carbohydrates and other nutrients is sensed by intestinal afferent neural transmission, and the information is relayed to other centers to modulate gastric motility (12, 39). Glucosensitive mesenteric and enteric neurons have been identified in the mammalian intestine (13, 23), and, recently, glucose-responsive enteric neurons were demonstrated to express the intestinal brush border Na+-dependent glucose transporter SGLT-1 protein (23). Therefore, in the process of the inhibitory action of acarbose on gastric emptying, it is possible that intestinal afferent neural transmission is altered through modulation of carbohydrate absorption.
The results of the present study demonstrate that acarbose modifies gut peptide release according to the timing and content of nutrient intake. Acarbose augmented release of CCK, GLP-1, and PYY in response to carbohydrate-containing meals (mixed meal and sucrose premeal) compared with controls, whereas it did not modify the hormone responses to a carbohydrate-free meal except for a brief and minor augmentation of plasma GLP-1, PYY, and GIP responses ~90 min after meal ingestion. These later effects of acarbose appear to be unrelated to carbohydrate absorption (see below). In the setting of a sucrose premeal followed by a carbohydrate-free meal, acarbose modified hormone responses to each meal differently. With the sucrose premeal acarbose augmented plasma CCK and GLP-1 compared with control, and the values nearly returned to basal levels before the intake of the carbohydrate-free meal. Acarbose did not modify integrated plasma CCK and GLP-1 in response to the carbohydrate-free meal after the sucrose premeal. On the other hand, acarbose augmented plasma PYY in response to the sucrose premeal and the values remained augmented while the carbohydrate-free meal was being ingested. These findings can be explained on the basis that during the 2 h between meals, unabsorbed carbohydrate residues may have moved from the proximal GLP-1- and CCK-releasing sites distally to sites at which PYY containing endocrine cells are abundant (1). We did not find any correlation between delayed emptying times of the carbohydrate-free meal and augmented PYY response. However, similar to the findings of a study investigating the effect of an amylase inhibitor on gastric emptying (20), attenuated response of plasma GIP by acarbose was negatively correlated with delayed gastric emptying times of the carbohydrate-free meal. These findings support the notion that acarbose-induced inhibition of gastric emptying is mainly related to inhibition/retardation of carbohydrate absorption. At the same time, augmentation of CCK, GLP-1 and PYY release by acarbose appears to be mainly related to its ability to alter carbohydrate absorption.
Augmented plasma GLP-1 response by acarbose in the mixed meal group was positively correlated with gastric emptying AUC. Furthermore, among the other plasma peptides measured, GLP-1 was the only significant determinant of gastric emptying. Augmentation of GLP-1 release by acarbose may be due to absorption of carbohydrates along a longer length of intestine, prolongation of the absorptive process, accelerated intestinal transit time, or increased delivery of carbohydrate residues to distal intestine. In humans, the inhibitory actions of GLP-1 on gastric emptying have been documented by several groups (16, 33). In rats, GLP-1 acts centrally and via capsaicin-sensitive vagal afferent nerves (19), similar to the actions of CCK, to inhibit gastric emptying. Thus, in the inhibition of gastric emptying of mixed nutrients by acarbose, GLP-1 may play a major role. Furthermore, considering our results together with the previous findings, it can be postulated that enhanced GLP-1 response by acarbose participates in the ileocolonic brake phenomenon when carbohydrate absorption is deranged, as occurs in malabsorption syndromes.
The reasons for acarbose-induced augmentation of PYY response may be similar to those operative in augmentation of GLP-1 response. In addition, in our acarbose groups, unabsorbed carbohydrate residues may have converted to SCFAs, which in turn may have caused augmented PYY response (7). CCK stimulates PYY release in dogs (28), but the relevance of this to our findings is not obvious. PYY is implicated as the mediator of the inhibitory action of SCFAs on gastric motility (7) and proposed as one of the hormonal mediators of the ileocolonic brake (34). Although the role played by PYY in our findings is not evident, it appears that inhibition of carbohydrate absorption by acarbose activates neurohormonal mediators, including PYY, that are known to exert inhibitory signals on the upper gut.
Our findings of enhanced CCK release by the acarbose in the mixed meal and sucrose premeal groups were contradictory to the findings of Uttenthal et al. (49), who found an unaltered CCK response. The divergent results are probably caused by different specificities of the assays used in the determination of plasma CCK concentrations (42). The availability of CCK receptor antagonists has facilitated the elucidation of CCK's role in the inhibition of gastric emptying, including emptying of carbohydrates (9, 30, 39). We did not find correlations between augmented CCK response by acarbose and gastric emptying times. However, in response to nutrient intake, plasma levels of CCK and its actions on motor functions of the gut are not necessarily congruent (9, 39). Accumulating evidence suggests that, after its release from the endocrine cells of the upper gut, CCK acts in a paracrine fashion on mucosal chemo- and nutrient-sensitive or mechanosensitive vagal afferents to exert its inhibitory actions on gut motility in addition to its hormonal effects (12, 32, 42a). Therefore, the role of CCK in the delayed gastric emptying times of the acarbose mixed meal group cannot be completely discarded.
The mechanism(s) by which acarbose enhances CCK release in response to
carbohydrate intake is not clearly evident. It is not likely that the
prolonged absorption time is the sole factor for enhanced peptide
release because the presence of acarbose was sensed fairly promptly by
CCK-releasing mechanisms (at 15 and 20 min with sucrose ingestion and
mixed meal, respectively). In humans the magnitude of
carbohydrate-induced CCK release is slightly less than that elicited by
isocaloric protein and fat (9, 25). To the best of our
knowledge, carbohydrate-stimulated CCK-releasing mechanisms have not
been elucidated. Further studies are required to investigate whether
inhibition of pancreatic amylase and/or -glucosidase by acarbose
results in a feedback signal to augment CCK release.
In our study groups that demonstrated acarbose-induced delay in gastric emptying, there was a correlation between augmented plasma responses of GLP-1 and PYY. As stated above, a longer length of intestinal exposure to carbohydrate absorption may have elicited augmented GLP-1 and PYY release in addition to the other possible mechanisms stated for PYY release. GLP-1 and PYY are costored in a proportion of mucosal L cells, which increase in number distally along the intestine, PYY-containing cells being more abundant in the colon (1). However, the release of GLP-1 and PYY in response to nutrients does not entirely involve similar mechanisms (3). With acarbose administration, the prompt, early rise in plasma GLP-1 after sucrose and mixed meal ingestion as documented in previous studies (36, 47) and in the present study, suggests that there are an adequate number of proximal GLP-1-containing L cells that are capable of sensing the interaction of carbohydrates with absorptive elements. At the same time, in rats, neuroendocrine loops originating in the proximal gut that signal the lower gut to release GLP-1 and PYY were described (11, 44).
Other factors for enhanced release of peptide hormones with acarbose
administration should also be considered. Nutrient-induced intestinal
neurohormonal signals generally involve the interaction of the nutrient
with the absorptive elements. Recent evidence suggests that the
nutrients do not necessarily need to be metabolized to elicit their
signaling function. Hence, 3-0-methyl glucose, which is transported by
the Na+-dependent glucose transporter SGLT-1 but is
nonmetabolizable, releases GLP-1 (43) and mimics the
action of intestinal glucose to inhibit gastric emptying
(40). Therefore, it is intriguing to postulate that
acarbose by binding to brush border -glucosidases and/or
-amylase
initiates signals for peptide release. This assumption is partially
supported by our findings that demonstrated that acarbose causes a
minor increase in plasma CCK with a nonnutrient water meal and delayed
minor increases in plasma GIP, GLP-1, and PYY in response to a
carbohydrate-free meal. Further studies are required to investigate the
effects of acarbose that are not related to carbohydrate absorption per
se on peptide release and gut motility.
In conclusion, our results are compatible with the notion that in healthy subjects acarbose delays gastric emptying by its ability to inhibit/retard carbohydrate absorption. As a result of alteration of carbohydrate absorption, it is likely that acarbose modifies the intestinal afferent neural transmission and the release of gut peptides, which in turn mediate the inhibitory action of acarbose on gastric emptying. Augmented plasma GLP-1 response may be a major mediator of the inhibitory action of acarbose on gastric emptying of a mixed meal, whereas augmented CCK and PYY responses may have contributory roles. It remains to be determined in healthy and diabetic subjects whether the inhibitory action of acarbose on gastric emptying contributes to its postprandial blood glucose blunting effect. Acarbose, in the absence of carbohydrate intake, modifies the release of nutrient-responsive peptide hormones in a minor fashion, which is probably caused by its interaction with carbohydrate absorptive sites or by other unknown factors.
![]() |
ACKNOWLEDGEMENTS |
---|
The technical assistance of Ayfer Ürün and Lene Albæk is appreciated.
![]() |
FOOTNOTES |
---|
*
F. Y. Enç and N.
This study was supported by grants from the Scientific and Technical
Research Council of Turkey (TÜB
Address for reprint requests and other correspondence: N. B. Ulusoy, Dept. of Internal Medicine, Univ. of Marmara Medical School,
81326 Haydarpaa, Istanbul, Turkey (E-mail:
nefiseulusoy{at}hotmail.com).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 14 November 2000; accepted in final form 18 April 2001.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Adrian, TE,
Ferri G-L,
Bacarese-Hamilton AJ,
Fuessl HS,
Polak JM,
and
Bloom SR.
Human distribution and release of a putative new gut hormone, peptide YY.
Gastroenterology
89:
1070-1077,
1985[ISI][Medline].
2.
Akn, HL,
and
Topçuo
lu H.
A comparison of several nonlinear optimization methods as multilayer perceptron training algorithms.
In: Proceedings of the Third Turkish Artificial Intelligence and Artificial Neural Networks Symposium. Ankara, Turkey: Middle-East Technical University, 1994, p. 75-84.
3.
Anini, Y,
Fu-Cheng X,
Cuber JC,
Kervran A,
Chariot J,
and
Rozé C.
Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat.
Pflügers Arch
438:
299-306,
1999[ISI][Medline].
4.
Back, TH,
Schultz M,
and
Khuri S.
Evolution strategies: an alternative evolution computation method.
In: Artificial Evolution, edited by Alliot JM,
Lutton E,
Ronald E,
Schoenhauer M,
and Snyers D.. Berlin: Springer, 1996, p. 3-20.
5.
Chiasson, J-L,
Josse RG,
Hunt JA,
Palmason C,
Rodger NW,
Ross SA,
Ryan EA,
Tan MH,
and
Wolever TMS
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus.
Ann Intern Med
121:
928-935,
1994
6.
Clissold, SP,
and
Edwards C.
Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
Drugs
35:
214-243,
1988[ISI][Medline].
7.
Cuche, G,
Cuber JC,
and
Malbert CH.
Ileal short-chain fatty acids inhibit gastric motility by a humoral pathway.
Am J Physiol Gastrointest Liver Physiol
279:
G925-G930,
2000
8.
Ferey-Roux, G,
Perrier J,
Forest E,
Marchis-Mouren G,
Puigserver A,
and
Santimone M.
The human pancreatic -amylase isoforms: isolation, structural studies and kinetics of inhibition by acarbose.
Biochim Biophys Acta
1388:
10-20,
1998[ISI][Medline].
9.
Fried, M,
Erlacher U,
Schwizer W,
Löchner C,
Koerfer J,
Behlinger C,
Jansen JB,
Lamers CB,
Harder F,
Bischof-Delaloye A,
Stalder GA,
and
Rovati L.
Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans.
Gastroenterology
101:
503-511,
1991[ISI][Medline].
10.
Fuessle, HS,
Adrian TE,
Uttenthal LO,
and
Bloom SR.
Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor.
Klin Wochenschr
66:
985-989,
1988[ISI][Medline].
11.
Fu-Cheng, X,
Anini Y,
Chariot J,
Castex N,
Galmiche J-P,
and
Rozé C.
Mechanism of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut.
Pflügers Arch
433:
571-579,
1997[ISI][Medline].
12.
Furness, JB,
Kunze WAA,
and
Clerc N.
Nutrient tasting and signaling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine, and immune responses.
Am J Physiol Gastrointest Liver Physiol
277:
G922-G928,
1999
13.
Hardcastle, J,
Hardcastle PT,
and
Sanford PA.
Effect of actively transported hexoses on afferent nerve discharge from rat small intestine.
J Physiol (Lond)
285:
71-84,
1978[Abstract].
14.
Heddle, R,
Fone D,
Dent J,
and
Horowitz M.
Stimulation of pyloric motility by intraduodenal dextrose in normal subjects.
Gut
29:
1349-1357,
1988[Abstract].
16.
Holst, JJ.
Enteroglucagon.
Annu Rev Physiol
59:
257-271,
1997[ISI][Medline].
17.
Holst, JJ,
and
Bersani M.
Assays for peptide products of somatostatin gene expression.
In: Methods in Neurosciences. Neuropeptide technology: Gene Expression and Neuropeptide Receptors, edited by Conn PM.. San Diego: Academic, 1991, vol. 5, p. 3-22.
18.
Hunt, JN,
Smith JL,
and
Jiang CJ.
Effect of meal volume and energy density on the gastric emptying of carbohydrates.
Gastroenterology
89:
1326-1330,
1985[ISI][Medline].
19.
Ïmeryüz, N,
Yeen BÇ,
Bozkurt A,
Co
kun T,
Villanueva-Penacarillo ML,
and
Ulusoy NB.
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.
Am J Physiol Gastrointest Liver Physiol
273:
G920-G927,
1997
20.
Jain, NK,
Boivin M,
Zinsmeister AR,
Brown ML,
Malagelada J-R,
and
Di Magno EP.
Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying.
Gastroenterology
96:
377-387,
1989[ISI][Medline].
21.
Juntti-Berggren, L,
Pigon J,
Hellström P,
Holst JJ,
and
Efendic S.
Influence of acarbose on postprandial insulin requirements in patients with Type 1 diabetes.
Diabetes Nutr Metab
13:
7-12,
2000[ISI][Medline].
22.
Krarup, T,
Madsbad S,
Moody AJ,
Regeur L,
Faber OK,
Holst JJ,
and
Sestoft L.
Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics.
J Clin Endocrinol Metab
56:
1306-1312,
1983[Abstract].
23.
Kirchgessner, A,
and
Lui M-T.
Identification and characterization of glucoresponsive neurons in the rat small intestine (Abstract).
Gastroenterology
114:
A778,
1999.
24.
Ladas, SD,
Frydas A,
Papadopoulos A,
and
Raptis SA.
Effects of -glucosidase inhibitors on mouth to caecum transit time in humans.
Gut
33:
1246-1248,
1992[Abstract].
25.
Liddle, RA,
Goldfine ID,
Rosen MS,
Taplitz RA,
and
Williams JA.
Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.
J Clin Invest
75:
1144-1152,
1985[ISI][Medline].
26.
Lin, HC,
Doty JE,
Reedy TJ,
and
Meyer JH.
Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient.
Am J Physiol Gastrointest Liver Physiol
256:
G404-G411,
1989
27.
Lin, HC,
Moller NA,
Wolinsky MM,
Kim BH,
Doty JE,
and
Meyer JH.
Sustained slowing of effect of lentils on gastric emptying of solids in humans and dogs.
Gastroenterology
102:
787-792,
1992[ISI][Medline].
28.
McFadden, DW,
Rudnicki M,
Kuvshinoff B,
and
Fischer JE.
Postprandial peptide YY release is mediated by cholecystokinin.
Surg Gynecol Obstet
175:
145-150,
1992[ISI][Medline].
29.
Mistiaen, W,
Van Hee R,
and
Blockx P.
Technical factors in labeling test meals to determine gastric emptying rate.
J Nucl Med Technol
24:
227-229,
1996.
30.
Moran, TH,
Field DG,
Knipp S,
Carrigan TS,
and
Schwartz GJ.
Endogenous CCK in the control of gastric emptying of glucose and maltose.
Peptides
18:
547-550,
1997[ISI][Medline].
31.
Morgan, LM.
Immunoassayable gastric inhibitory polypeptide. Investigations into its role in carbohydrate metabolism.
Ann Clin Biochem
16:
6-1,
1979[ISI][Medline].
32.
Moriarty, P,
Dimaline R,
Thompson DG,
and
Dockray GJ.
Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons.
Neuroscience
79:
905-913,
1997[ISI][Medline].
33.
Nauck, MA,
Niedereichholz U,
Ettler R,
Holst JJ,
Ørskov C,
Ritzel R,
and
Schmiegel WH.
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Am J Physiol Endocrinol Metab
273:
E981-E988,
1997
34.
Nightingale, JMD,
Kamm MA,
van der Sijp JRM,
Ghatei MA,
Bloom SR,
and
Lennard-Jones JE.
Gastrointestinal hormones in short bowel syndrome peptide YY may be the "colonic brake" to gastric emptying.
Gut
39:
267-272,
1996[Abstract].
35.
Ørskov, C,
Rabenhøj L,
Wettergren A,
Kofod H,
and
Holst JJ.
Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
Diabetes
43:
535-539,
1994[Abstract].
36.
Qualmann, C,
Nauck MA,
Holst JJ,
Ørskov C,
and
Creutzfeldt W.
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut.
Scand J Gastroenterol
30:
892-896,
1995[ISI][Medline].
37.
Radziuk, J,
Kemmer F,
Morishima T,
Berchtold P,
and
Vranic M.
The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method.
Diabetes
33:
207-213,
1984[Abstract].
38.
Ranganath, L,
Norris F,
Morgan L,
Wright J,
and
Marks V.
Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect.
Diabet Med
15:
120-124,
1998[ISI][Medline].
39.
Raybould, HE,
and
Hölzer H.
Dual capsaicin-sensitive afferent pathways mediate inhibition of gastric emptying in rat induced by intestinal carbohydrate.
Neurosci Lett
141:
236-238,
1992[ISI][Medline].
40.
Raybould, HE,
and
Zittel TT.
Inhibition of gastric motility induced by intestinal glucose in awake rats: role of Na+-glucose co-transporter.
Neurogastroenterol Motil
7:
9-14,
1995[ISI][Medline].
41.
Rehfeld, JF.
Accurate measurement of cholecystokinin in plasma.
Clin Chem
44:
991-1001,
1998
42.
Rehfeld, JF.
How to measure cholecystokinin in tissue, plasma and cerebrospinal fluid.
Regul Pept
78:
31-39,
1998[ISI][Medline].
42a.
Richards, W,
Hillsley K,
Eastwood C,
and
Grundy D.
Sensitivity of vagal mucosal afferents to cholecystokinin and its role in afferent signal transduction in the rat.
J Physiol (Lond)
497:
473-481,
1996[Abstract].
43.
Ritzel, U,
Fromme A,
Ottleben M,
Leonhardt U,
and
Ramadori G.
Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum.
Acta Diabetol
34:
18-21,
1997[ISI][Medline].
44.
Rocca, AS,
and
Brubaker PL.
Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.
Endocrinology
140:
1687-1694,
1999
45.
Ropert, A,
Cherbut C,
Rozé C,
Le Quellec A,
Holst JJ,
Fu-Cheng X,
Bruley des Varannes S,
and
Galmiche JP.
Colonic fermentation and proximal gastric tone in humans.
Gastroenterology
111:
289-296,
1996[ISI][Medline].
46.
Ruppin, H,
Hagel J,
Feuerbach W,
Schutt H,
Pichl J,
Hillebrand I,
Bloom S,
and
Domschke W.
Fate and effects of the -glucosidase inhibitor acarbose in humans.
Gastroenterology
95:
93-99,
1988[ISI][Medline].
47.
Schirra, J,
Katschinski M,
Weidmann C,
Schäfer T,
Wank U,
Arnold R,
and
Göke B.
Gastric emptying and release of incretin hormones after glucose ingestion in humans.
J Clin Invest
97:
92-103,
1996
48.
Siegel, JA,
Urbain J-L,
Adler LP,
Charkes ND,
Maurer AH,
Krevsky B,
Knight LC,
Fisher RS,
and
Malmud LS.
Biphasic nature of gastric emptying.
Gut
29:
85-89,
1988[Abstract].
49.
Uttenthal, LO,
Ukponmwan OO,
Ghiglione M,
and
Bloom SR.
Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man.
Dig Dis Sci
32:
139-144,
1987[ISI][Medline].